A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis - PubMed (original) (raw)
Clinical Trial
doi: 10.1136/ard.2003.020347. Epub 2004 Jul 8.
K Pavelka, J Vencovsky, H Stahl, B Rozman, M Genovese, A J Kivitz, J Alvaro, G Nuki, D E Furst, G Herrero-Beaumont, I B McInnes, P Musikic, P P Tak
Affiliations
- PMID: 15242865
- PMCID: PMC1755211
- DOI: 10.1136/ard.2003.020347
Clinical Trial
A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis
J van Holten et al. Ann Rheum Dis. 2005 Jan.
Abstract
Objective: To assess the efficacy of interferon beta (IFN beta) in combination with methotrexate in treatment of patients with rheumatoid arthritis.
Methods: 209 patients with active rheumatoid arthritis, who had been on methotrexate for at least six months and at a stable dose for four weeks before study entry, were randomised in double blind fashion to receive placebo (0.05 ml or 0.5 ml), IFN beta 2.2 microg (0.05 ml), or IFN beta 44 microg (0.5 ml), given subcutaneously three times weekly for 24 weeks. The primary efficacy measure was a change in radiological scores at week 24. The secondary endpoint was the proportion of patients who met the ACR 20% improvement criteria at the end of the study. Synovial biopsy specimens were obtained before and after treatment from a subset of patients. Immunohistochemistry was used to detect the presence of inflammatory cells and the results were measured by digital image analysis. Collagen crosslinks were measured in urine at different times throughout the study.
Results: Analysis of radiological scores and clinical variable showed no changes in any of the groups, and there were no differences between the groups. On microscopic analysis of synovial tissue there was no significant change in the scores for infiltration by inflammatory cells after IFN beta treatment. Urinary levels of collagen crosslinks were unchanged between the treatment groups.
Conclusions: At the doses tested, treatment with IFN beta three times weekly in combination with methotrexate did not have a clinical or radiological effect in patients with rheumatoid arthritis.
Figures
Figure 1
Patient disposition.
Figure 2
American College of Rheumatology 20% (ACR20) response in the treatment groups (placebo groups combined).
Similar articles
- A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ. Weinblatt ME, et al. N Engl J Med. 1999 Jan 28;340(4):253-9. doi: 10.1056/NEJM199901283400401. N Engl J Med. 1999. PMID: 9920948 Clinical Trial. - A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate.
Genovese MC, Lee E, Satterwhite J, Veenhuizen M, Disch D, Berclaz PY, Myers S, Sides G, Benichou O. Genovese MC, et al. Ann Rheum Dis. 2013 Sep 1;72(9):1453-60. doi: 10.1136/annrheumdis-2012-202864. Epub 2013 Apr 18. Ann Rheum Dis. 2013. PMID: 23599435 Clinical Trial. - Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.
Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martín Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Klareskog L, et al. Lancet. 2004 Feb 28;363(9410):675-81. doi: 10.1016/S0140-6736(04)15640-7. Lancet. 2004. PMID: 15001324 Clinical Trial. - Synovial tissue analysis in clinical trials.
Bresnihan B, Baeten D, Firestein GS, Fitzgerald OM, Gerlag DM, Haringman JJ, McInnes IB, Reece RJ, Smith MD, Ulfgren AK, Veale DJ, Tak PP; OMERACT 7 Special Interest Group. Bresnihan B, et al. J Rheumatol. 2005 Dec;32(12):2481-4. J Rheumatol. 2005. PMID: 16331792 Review. - From disease modification to disease control in rheumatoid arthritis.
Furst DE. Furst DE. Clin Exp Rheumatol. 1997 May-Jun;15 Suppl 17:S63-6. Clin Exp Rheumatol. 1997. PMID: 9266134 Review.
Cited by
- Serum level of IFNβ distinguishes early from late relapses after biologics withdrawal in rheumatoid arthritis.
Sakashita E, Nagatani K, Endo H, Minota S. Sakashita E, et al. Sci Rep. 2022 Oct 3;12(1):16547. doi: 10.1038/s41598-022-21160-0. Sci Rep. 2022. PMID: 36192530 Free PMC article. - Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders.
Brummer T, Ruck T, Meuth SG, Zipp F, Bittner S. Brummer T, et al. Ther Adv Neurol Disord. 2021 Aug 23;14:17562864211035542. doi: 10.1177/17562864211035542. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34457039 Free PMC article. Review. - A comprehensive transcriptomic analysis of alternate interferon signaling pathways in peripheral blood mononuclear cells in rheumatoid arthritis.
Han L, Tu S, Shen P, Yan J, Huang Y, Ba X, Li T, Lin W, Li H, Yu K, Guo J, Huang Y, Qin K, Wang Y, Chen Z. Han L, et al. Aging (Albany NY). 2021 Aug 25;13(16):20511-20533. doi: 10.18632/aging.203432. Epub 2021 Aug 25. Aging (Albany NY). 2021. PMID: 34432649 Free PMC article. - Early phase and adaptive design clinical trials in rheumatoid arthritis: a systematic review of early phase trials.
Pickles T, Christensen R, Tam LS, Simon LS, Choy EH. Pickles T, et al. Rheumatol Adv Pract. 2018 Oct 17;2(2):rky045. doi: 10.1093/rap/rky045. eCollection 2018. Rheumatol Adv Pract. 2018. PMID: 31431982 Free PMC article. - Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis.
Chen Z, Bozec A, Ramming A, Schett G. Chen Z, et al. Nat Rev Rheumatol. 2019 Jan;15(1):9-17. doi: 10.1038/s41584-018-0109-2. Nat Rev Rheumatol. 2019. PMID: 30341437 Review.
References
- Lancet. 1999 Jan 23;353(9149):259-66 - PubMed
- Arthritis Rheum. 1994 Oct;37(10):1492-8 - PubMed
- Rheumatology (Oxford). 1999 Apr;38(4):362-9 - PubMed
- Ann Neurol. 1999 Aug;46(2):197-206 - PubMed
- J Rheumatol. 2000 Jan;27(1):261-3 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous